A review by the New England Journal of Medicine of data from a 2010 study it published on CareFusion‘s (NYSE:CFN) ChloraPrep antiseptic found that both the company and the doctor in charge of the study acted appropriately, the journal told MassDevice.com today.
CareFusion Corp.
Terumo inks distribution deals with CareFusion, Nonin Medical
Terumo Corp. (TYO:4543) sat on both sides of the table in inking a pair of distribution deals with CareFusion (NYSE:CFN) and Nonin Medical.
CareFusion affirms full-year outlook amid 10% profit slide in Q2
Analysts are taking a cautious approach to CareFusion (NYSE:CFN) amid increasing costs and a 10% drip in profits for the company’s 2nd quarter.
NEJM reviews ChloraPrep study in patient safety controversy
Hidden financial ties rattle top health quality group
by Marshall Allen, ProPublica
National Quality Forum changed policy ahead of kickbacks flap
Influential patient safety board cut ties with doc before CareFusion kickbacks case
CareFusion pays out $41M in ChloraPrep settlement
CareFusion (NYSE:CFN) said it closed out the $41 million settlement of a 2-year federal investigation into the marketing of its ChloraPrep antiseptic skin preparation wipes.
GE Healthcare recall gets FDA’s highest-risk label
CareFusion closes Vital Signs purchase
CareFusion (NYSE:CFN) said it completed a deal with GE Healthcare (NYSE:GE) to acquire Vital Signs for $500 million.
CareFusion puts $100M in Israeli infusion pumps
CareFusion (NYSE:CFN) announced today that it invested $100 million into Israel-based Caesarea Medical Electronics, taking a 40% stake in the infusion pump company.